Human mesenchymal stem cell-derived extracellular vesicles from lean patients reduced cardiac hypertrophy, fibrosis, and blood pressure in renovascular hypertensive mice more than obese EVs.
Does injection of human A-MSC-derived EVs from lean subjects improve cardiac hypertrophy and fibrosis in mice with renovascular hypertension compared to EVs from obese subjects?
Human A-MSC-derived EVs from lean subjects are more effective than those from obese subjects in blunting hypertensive cardiac injury and remodeling in a mouse model of renovascular hypertension.
p-value: p=<0.05
Injection of A-MSC-derived EVs harvested from patients who are lean can resolve myocardial injury in mice with experimental renovascular hypertension more effectively than A-MSC-derived EVs from patients with obesity. These observations underscore and might have important ramifications for the self-healing capacity of patients with obesity and for the use of autologous EVs as a regenerative tool.
Hong et al. (Fri,) conducted a other in Renovascular hypertension. Human A-MSC-derived lean extracellular vesicles (EVs) vs. Obese EVs or Vehicle was evaluated on Cardiac left ventricular function, blood pressure, and myocardial fibrosis (p=<0.05). Human mesenchymal stem cell-derived extracellular vesicles from lean patients reduced cardiac hypertrophy, fibrosis, and blood pressure in renovascular hypertensive mice more than obese EVs.